Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer

Journal of Urology

Volumn 174, Issue 3, 2005, Pages 1115-1118

  Brocks, Carsten Philipp ^a   Büttner, Hartwig ^b   Böhle, Andreas ^c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c HELIOS AGNES KARLL HOSPITAL   (Germany)

Author keywords

Bladder; carcinoma; Intravesical; Transitional cell; mice; gemcitabine; instillation

Indexed keywords

GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER CAPACITY; BLADDER INJURY; BLADDER IRRIGATION; BLADDER WALL; CANCER CELL; CANCER MODEL; CANCER TRANSPLANTATION; CAUTERIZATION; CELL SUSPENSION; CHI SQUARE TEST; CONTROLLED STUDY; DIURESIS; DRUG EFFICACY; DRUG INSTILLATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPERFICIAL CANCER; TIME; TUMOR CELL;

EID: 23744477856     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000168657.51551.49     Document Type: Article

References (19)

1. Soloway, M. S.: The management of superficial bladder cancer. Cancer, suppl., 45: 1856, 1980
2. Sidransky, D., Frost, P., von Eschenbach, A., Oyasu, R., Preisinger, A. and Vogelstein, B.: Clonal origin bladder cancer. N. Engl J Med, 326: 737, 1992
3. See, W. A. and Chapman, W. H.: Tumor cell implantation following neodymium-YAG bladder injury: a comparison to electrocautery injury. J Urol, 137: 1266, 1987
4. Pode, D., Alon, Y., Horowitz, A. T., Vlodavsky, I. and Biran, S.: The mechanism of human bladder tumor implantation in an in vitro model. J Urol, 136: 482, 1986
5. Soloway, M. S. and Masters, S.: Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer, 46: 1158, 1980
6. Gunther, J. H., Jurczok, A., Wulf, T., Brandau, S., Deinert, I., Jocham, D. et al: Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res, 59: 2834, 1999
7. Lamm, D. L., Riggs, D. R., Traynelis, C. L. and Nseyo, U. O.: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol, 153: 1444, 1995
8. Sylvester, R. J., Oosterlinck, W. and van der Meijden, A. P. M.: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol, 171: 2186, 2004
9. van der Meijden, A. P.: The use of the marker tumor concept in Ta, T1 bladder cancer: is it justified? Urol Oncol, 7: 31, 2002
10. Plunkett, W., Huang, P., Searcy, C. E. and Gandhi, V.: Gemcitabine: preclinical pharmacology and mechanism of action. Semin Oncol, 23: 3, 1996
11. Bold, R. J., Chandra, J. and McConkey, D. J.: Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol, 6: 279, 1999
12. Stadler, W. M., Kuzel, T., Roth, B., Raghavan, D. and Dorr, F. A.: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol, 15: 3394, 1997
13. von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J. et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 18: 3068, 2000
14. Witjes, J. A., Vriesema, J. L., van der Heijden, A. G., Peters, G. J. and Schalken, J. A.: Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. Eur Urol, 44: 615, 2003
15. Kilani, R. T., Tamimi, Y., Karmali, S., Mackey, J., Hanel, E. G., Wong, K. K. et al: Selective cytotoxicity of gemcitabine in bladder cancer cell lines. Anticancer Drugs, 13: 557, 2002
16. Dalbagni, G., Russo, P., Sheinfeld, J., Mazumdar, M., Tong, W., Rabbani, F. et al: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol, 20: 3193, 2002
17. Palou, J., Carcas, A., Segarra, J., Duque, B., Salvador, J., Garcia-Ribas, I. et al: Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol, 172: 485, 2004
18. Oosterlinck, W., Kurth, K. H., Schröder, F., Bultinck, J., Hammond, B. and Sylvester, R.: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol, 149: 749, 1993
19. Kaasinen, E., Rintala, E., Hellstrom, P., Viitanen, J., Juusela, H., Rajala, P. et al: Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol, 42: 167, 2002